Introduction {#Sec1}
============

Binge eating disorder (BED) is a psychiatric disorder, characterized by recurrent binge eating episodes which are not followed by inappropriate compensatory behaviors. BED appears to affect a broader spectrum of the population than anorexia nervosa (AN) and bulimia nervosa (BN) \[[@CR1]--[@CR4]\], resulting in a clinically significant disorder \[[@CR5]\].

BED was originally introduced in the 4th Edition of The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) as a sub-category of eating disorders not otherwise specified (EDNOS) \[[@CR6]\]. In the new DSM-5, published in May 2013, BED was included as a full diagnostic entity \[[@CR7]\]. In the DSM-IV, for a provisional diagnosis of BED, binge eating must occur on at least 2 days per week over a 6-month period \[[@CR6]\]. In contrast, according to the new DSM-5 criteria, BED is characterized by at least one binge eating episode per week for three months \[[@CR7]\].

The aim of this study is to undertake a systematic review of the published literature on the epidemiology, HRQoL and economic burden of BED. To our knowledge, no comprehensive review encompassing these topics has been published to date. However, this information consolidated in a single literature review provides a holistic overview of the public health importance of BED.

Materials and methods {#Sec2}
=====================

This review of evidence on the burden of BED was a part of a comprehensive literature review on the epidemiology, and the HRQoL and economic burden of eating disorders. A systematic literature search was conductedin July 2013 using Medline and Embase (via Scopus), PsycINFO, PsycARTICLES, Academic Search Complete, CINAHL Plus, Business Source Premier (via Ebsco Host) and Cochrane Library. Search terms were combinations of terms related to the disease (BED, AN, BN and EDNOS), epidemiology (prevalence, incidence and mortality), HRQoL burden (quality of life, health burden, humanistic burden, quality adjusted life years and disability adjusted life years) and economic burden (direct healthcare costs, direct patient and caregiver cost, wider societal cost). For case of studies related to HRQoL and/or economic burden, there were no pre-defined publication date limits. To get up to date epidemiological data, literature search on epidemiology was limited to studies published between 2009 and 2013. Specification of the review protocol is provided in Online Resource 1.

Search results were considered in two steps. Initially, titles and abstracts of all articles were screened using the following inclusion criteria: (1) the article was written in English; (2) the article was related to eating disorders; and (3) the article studied the epidemiology, HRQoL burden and/or economic burden of eating disorders. Those articles deemed relevant were analyzed in full text. During the full text review only publications in which BED was defined using either the DSM-IV or DSM-5 criteria (proposed or published), and BED sample was clearly separated from other eating disorders were included; reasons for exclusion were: (1) the article was not written in English; (2) the article was not published in peer-reviewed journals; (3) the article was editorial, letter, case report or review; (4) the article was not specific to BED; or (5) the article had other objective than studying the epidemiology, HRQoL and/or economic burden of BED. References of relevant articles were screened for additional eligible studies. Literature screening was conducted by two reviewers independently; disagreements were resolved by the principal researcher.

Data extraction focused on and was limited to findings relevant to the research topic. The following information was extracted from each study: (1) first author and year of publication; (2) country; (3) study design; (4) study year; (5) included eating disorder(s); (6) diagnostic method and criteria for BED; (7) characteristics of study sample \[sample size,  % of female, mean age, mean body mass index (BMI)\]; (8) epidemiological data \[incidence, prevalence (lifetime, 12-month, point), mortality, suicide (ideation, attempt)\]; (9) data on the HRQoL burden of BED (HRQoL instrument, HRQoL data) (10) data on healthcare utilization of BED patients (data source, resource utilization categories, main findings); and (11) data on healthcare costs and/or societal costs related to BED (perspective of the analysis, data source, year of pricing, cost categories, cost data). For interventional studies, in which HRQoL was assessed, only the baseline HRQoL data were extracted as this review investigated the association between BED and patient's HRQoL and not the efficacy/effectiveness of different interventions on HRQoL in BED.

In this review, prevalence and incidence were defined as follows: incidence as the number of new cases of a disorder in the population over a specified period related to the number of persons at risk at the beginning of the period (cumulative incidence) or to the person-time of observation (incidence rate); point prevalence as the proportion of persons affected with the disorder at a specific point in time; 12-month prevalence rate as the point prevalence plus the annual cumulative incidence (the proportion of people with new cases in the following year); lifetime prevalence as the proportion of people that had the disorder at any point in their life.

In order to compare cost data across studies, costs were extrapolated to annual costs per patient and were inflated to the year of 2012 using country specific gross domestic product (GDP) deflators, and converted into United States (US) dollars (\$), using purchasing power parities. If the year of pricing was not referenced, then the midpoint in the observation period was assumed as the base year. If no observation period was reported, the year of publication was adopted.

Quality assessment of the included studies was performed using the strengthening the reporting of observational studies in epidemiology (STROBE) checklist for cohort, case--control, and cross-sectional studies \[[@CR8]\]. The results for each study were summarized as the percentage of the fulfilled criteria. STROBE criteria that were not applicable to a study were excluded from the quality assessment. All studies were independently assessed by two researchers, disagreements were resolved by the principal researcher.

Results {#Sec3}
=======

Search results {#Sec4}
--------------

The database search resulted in 7,211 hits. Screening of titles and abstracts identified 540 potentially eligible articles. Two additional records were identified through hand search of the references of relevant articles. After the review of relevant full text articles, 49 studies were included in this systematic review. The flow diagram of the systematic literature search, based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) template \[[@CR9]\], is presented in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1The flow diagram of the systematic literature search. *BED* binge eating disorder. *HRQoL* health-related quality of life

Most studies (*n* = 40) were cross-sectional \[[@CR2]--[@CR4], [@CR19]--[@CR55]\], 7 longitudinal \[[@CR10]--[@CR12], [@CR15]--[@CR18]\], and 2 were database analyses \[[@CR13], [@CR14]\]. Included studies originated from 23 countries, with over half (*n* = 25) conducted in the US. The sample sizes of the included studies ranged from 31 \[[@CR19]\] to 77,807 \[[@CR12]\], with a mean ages from 13.0 \[[@CR16]\] to 49.8 \[[@CR20]\] years. Many studies only included females (*n* = 18) but in those including both sexes, females were over-represented. Diagnosis of BED was made using DSM-IV criteria in 44 \[[@CR2]--[@CR4], [@CR10], [@CR12]--[@CR15], [@CR17]--[@CR20], [@CR22]--[@CR30], [@CR32]--[@CR41], [@CR43]--[@CR55]\], using the proposed DSM-5 criteria in 3 \[[@CR11], [@CR16], [@CR31]\], and using both DSM-IV and the proposed DSM-5 criteria in 2 studies \[[@CR21], [@CR42]\]. The general characteristics of the reviewed studies are presented in Online Resource 2.

Included studies (*n* = 49) fulfilled between 26.5 \[[@CR21]\] and 84.4 % \[[@CR3]\] of the STROBE criteria. Details of the quality assessment are provided in Online Resource 3.

Epidemiology {#Sec5}
------------

Only one study reported incidence rate for BED \[[@CR16]\]. A sample of 496 adolescent females over an 8-year period found the incidence of BED (DSM-5) to be 343 per 100,000 person-years \[[@CR16]\].

Point prevalence rate for BED was reported in 22 studies \[[@CR12], [@CR14], [@CR20]--[@CR39]\], 12-month prevalence rate in 4 studies \[[@CR2]--[@CR4], [@CR13]\] and lifetime prevalence rate in 11 studies \[[@CR2]--[@CR4], [@CR13], [@CR16], [@CR17], [@CR21], [@CR36], [@CR40]--[@CR42]\]. Detailed information on the reported prevalence rates are presented in Online Resource 2. Point prevalence rates, not limited to population-based estimates varied between 0.1 % (in a sample of pregnant women, 6--12 months prior pregnancy) \[[@CR27]\] and 34.1 % (in a sample with type 2 diabetes) \[[@CR20]\] using DSM-IV criteria, and 0.6 % (in a sample of female high school and university students) \[[@CR31]\] to 1.7 % (in a sample of first degree relatives of BED patients) \[[@CR21]\] using the proposed DSM-5 criteria. The 12-month prevalence rate of BED, not limited to population-based estimates ranged between 0.1 % (in a large community sample of people over 18 years of age) \[[@CR3]\] and 1.1 % (in a sample of Latino) \[[@CR13]\] using DSM-IV criteria. Lifetime prevalence for BED, not limited to population-based estimates was 0.17 % (in a sample of adult female twins) \[[@CR42]\] to 8.8 % (in a sample of outpatients with bipolar disorder) \[[@CR40]\] using DSM-IV criteria and 0.2 % (in a sample of adult female twins) \[[@CR42]\] to 3.6 % (in a sample of first degree relatives of BED patients) \[[@CR21]\] using the proposed DSM-5 criteria.

In three studies the lifetime prevalence of BED (DSM-IV) was 1.5--6 times higher in women than in men \[[@CR3], [@CR4], [@CR21]\]. Hudson et al. \[[@CR21]\]. found no difference in the proportion of women and men regarding the DSM-IV and the proposed DMS-5 lifetime prevalence of BED (Online Resource 2). Sex difference was also observed in point and 12-month prevalence rates (Online Resource 2). The majority of BED cases occurred first in people's lives between the ages of 12.4 and 24.7 years \[[@CR3], [@CR4], [@CR16], [@CR43]\]; however, the prevalence of BED continued to rise until 40 years old \[[@CR3]\]. From the reviewed articles information on ethnic or racial differences in prevalence of BED was limited and inconsistent. Azarbard et al. \[[@CR24]\] found no significant differences in the prevalence of BED among Hispanic, African American and White women (Online Resource 2). However, Perez et al. \[[@CR14]\] reported higher prevalence for BED among Hispanic (2.3 %) and Black individuals (1.6 %) compared to White individuals (1.0 %).

Several studies examined the association of BED with physical and psychiatric comorbidities. In the study Kessler et al. \[[@CR2]\] the odds ratio (OR) for BED was 2.9 for individuals with diabetes, 2.2 for hypertension, 1.6 for stroke and 1.3 for heart disease (population-based estimates). Point prevalence of BED (DSM-IV) in overweight/obese individuals was reported to be 5.9 % in a sample with serious mental illness \[[@CR30]\], 13.4 % in a sample waiting for bariatric surgery \[[@CR39]\] and 23.9 % in a sample seeking weight loss treatment \[[@CR34]\]. The OR for lifetime BED was 0.7 for BMI \< 18.5, 1.0 for BMI 18.5--24.9, 1.3 for BMI 25--29.9, 3.1 for BMI 30--34.9, 3.0 for BMI 35--39.9 and 6.6 for BMI \> 40 (population-based estimates) \[[@CR2]\]. Lifetime prevalence of BED was found to be elevated in patients with obsessive--compulsive disorder and bipolar I or II disorders \[[@CR36], [@CR40]\]. Compared to a non-eating disorder group, the mean scores in Beck anxiety inventory was higher for the BED group (23 vs. 13, *p* \< 0.001) and for the Beck depression inventory (23 vs. 15, *p* \< 0.001) \[[@CR36]\]. Several studies reported that BED occurred in a significant number of women during pregnancy (1.8--7 %) and in the post-partum period (2.7--3.1 %) \[[@CR12], [@CR27], [@CR28], [@CR32]\].

Mortality for BED was not reported in any of the included studies and only 3 studies described data on suicide attempt and/or ideation in BED patients \[[@CR4], [@CR22], [@CR44]\]. When comparing asymptomatic and BED individuals, among a school-based sample of youth the ORs for suicidal ideation and attempt were 2.6 and 3.1, respectively \[[@CR22]\]. In the studies conducted by Carano et al. \[[@CR44]\] and Swanson et al. \[[@CR4]\], 27.5 % (in adults) to 34.4 % (in adolescents) of individuals with BED had suicidal ideations and the frequency of suicidal attempts was 12.5 % (in adults) to 15.1 % (in adolescents).

Health-related quality of life burden {#Sec6}
-------------------------------------

Sixteen studies reported data on the HRQoL burden of BED (Table [1](#Tab1){ref-type="table"}) \[[@CR10], [@CR11], [@CR14], [@CR15], [@CR18], [@CR19], [@CR34], [@CR43], [@CR45]--[@CR52]\].Various questionnaires were used to measure HRQoL in the studies. All but one study used validated HRQoL questionnaires (Table [1](#Tab1){ref-type="table"}). Perez et al. \[[@CR14]\] used a self-developed instrument. General HRQoL measures included the Extended Satisfaction With Life Scale (ESWLS) \[[@CR10]\], EuroQol Five Dimensional Questionnaire (EQ-5D-3L) \[[@CR43]\], Short Form-36 (SF-36) \[[@CR11], [@CR19], [@CR45]--[@CR48], [@CR50]\], Short Form-12 (SF-12) \[[@CR49]\] or World Health Organization Brief Quality of Life Assessment (WHOQOL-BREF) \[[@CR15], [@CR49]\]. The SF-36 (*n* = 7) was the most commonly used HRQoL questionnaire. An obesity-specific measure was used in 5 studies (Impact of Weight on Quality of Life Lite (IWQOL-LITE) \[[@CR18], [@CR45], [@CR51], [@CR52]\] and Obesity Related Well-Being (ORWELL) \[[@CR34]\]).Table 1Summary of the health related quality of life data of the included studiesFirst author, referenceHRQoL instrumentStudy sampleSample sizeHRQoL data, baseline mean (SD)Cassin \[[@CR10]\]^a^ESWLSBED, AMI54ESWLS General life score: 16.5 (7.8), ESWLS Social life score: 14.1 (8.0), ESWLS Sex life score: 12.0 (8.0), ESWLS Self score: 14.1 (6.5), ESWLS Physical appearance score: 7.1 (3.9), ESWLS Family score: 19.5 (8.8), ESWLS Relationships score: 17.5 (10.1)BED, control (no AMI)54ESWLS General life score: 17.1 (8.0), ESWLS Social life score: 15.8 (8.5), ESWLS Sex life score: 13.5 (8.7), ESWLS Self score: 16.0 (6.9), ESWLS Physical appearance score: 8.7 (4.9), ESWLS Family score: 18.4 (10.1), ESWLS Relationships score: 19.2 (9.3)De Zwaan \[[@CR45]\]^b^SF-36BED, postoperative9SF-36 PCS: 42.2 (8.9), SF-36 MCS: 45.7 (10.4)No BED, postoperative69SF-36 PCS: 47.2 (10.2), SF-36 MCS: 52.8 (7.8)De Zwaan \[[@CR46]\]^b^SF-36BED, preoperative19SF-36 PCS: 31.1 (9.2), SF-36 MCS: 49.8 (10.1)No BED, preoperative91SF-36 PCS: 28.1 (6.8), SF-36 MCS: 44.7 (9.5)IWQOL-LITEBED, preoperative19IWQOL-LITE total score: 46.7 (17.6)No BED, preoperative91IWQOL-LITE total score: 34.0 (9.9)Doll \[[@CR47]\]^b^SF-36BED18SF-36 PCS: 46.3 (9.1), SF-36 MCS: 40.8 (9.0)AN6SF-36 PCS: 43.4 (9.0), SF-36 MCS: 45.54 (8.9)BN45SF-36 PCS: 47.2 (9.5), SF-36 MCS: 43.8 (9.4)No ED1,219SF-36 PCS: 48.1 (16.7), SF-36 MCS: 49.8 (16.5)Faulconbridge \[[@CR11]\]^a^SF-36BED, bariatric surgery36SF-36 PCS: 37.7 (1.7), SF-36 MCS: 43.1 (1.6)BED, lifestyle modification49SF-36 PCS: 40.8 (1.3), SF-36 MCS: 45.4 (2.0)Grenon \[[@CR43]\]^b^EQ-5D-3LBED105EA-5D-3L index score: 0.77 (0.2)Hsu \[[@CR19]\]^b^SF-36BED37SF-36 PCS: 33.0^d^, SF-36 MCS: 45.0^d^Kolotkin \[[@CR52]\]^b^IWQOL-LITEBED95IWQOL-LITE total score: 51.5 (21.9)No BED435IWQOL-LITE total score: 65.3 (19.8)Masheb \[[@CR48]\]^b^SF-36BED94SF-36 PCS: 47.3 (10.2), SF-36 MCS: 39.7 (11.0)BED, BMI ≥ 3071SF-36 PCS: 45.3 (9.6), SF-36 MCS: 39.3 (10.6)BED, BMI \< 3023SF-36 PCS: 53.6 (9.4), SF-36 MCS: 41.0 (12.2)Mond \[[@CR49]\]^b^SF-12BED10SF-12 PCS: 40.2 (13.1), SF-12 MCS: 30.4 (8.0)AN, restricting type19SF-12 PCS: 45.4 (10.3), SF-12 MCS: 38.4 (11.1)AN, purging type15SF-12 PCS: 46.8 (10.0), SF-12 MCS: 27.0 (7.4)BN40SF-12 PCS: 49.3 (10.1), SF-12 MCS: 27.6 (9.4)Normal control (no ED)495SF-12 PCS: 50.7 (8.8), SF-12 MCS: 47.4 (10.3)WHOQOL-BREFBED10WHOQOL-BREF QoLP: 2.2 (0.5), WHOQOL-BREF QoLS: 2.2 (1.0)AN, restricting type19WHOQOL-BREF QoLP: 2.7 (0.9), WHOQOL-BREF QoLS: 3.6 (1.0)AN, purging type15WHOQOL-BREF QoLP: 2.1 (0.7), WHOQOL-BREF QoLS: 2.6 (1.1)BN40WHOQOL-BREF QoLP: 2.4 (0.7), WHOQOL-BREF QoLS: 3.1 (1.0)Normal control (no ED)495WHOQOL-BREF QoLP: 3.7 (0.6), WHOQOL-BREF QoLS: 3.7 (0.8)Padierna \[[@CR50]\]^b^SF-36BED17SF-36 PCS: 36.5^d^, MCS: 32.0^d^AN, restricting type56SF-36 PCS: 44.0^d^, SF-36 MCS: 34.0^d^AN, purging type60SF-36 PCS: 43.5^d^, SF-36 MCS: 28.0^d^BN64SF-36 PCS: 43.0^d^, SF-36 MCS: 30.0^d^Perez \[[@CR14]\]^c^self-developedNon-obese without BED12,063Physical health score: 2.6 (0.7), Mental health score: 2.2 (1.0)Non-obese with BED124Physical health score: 2.5 (0.8), Mental health score: 2.5 (1.2)Obese without BED4,585Physical health score: 2.6 (0.8), Mental health score: 2.2 (1.0)Obese with BED126Physical health score: 2.4 (0.8), Mental health score: 2.8 (1.1)Ricca \[[@CR34]\]^b^ORWELLBED105ORWELL total score: 54.3 (21.2)BED subthreshold146ORWELL total score: 53.0 (20.3)Overweight non-BED187ORWELL total score: 56.0 (22.2)Rieger \[[@CR51]\]^b^IWQOL-LITEBED56IWQOL-LITE total score: 74.0 (19.3)No BED62IWQOL-LITE total score: 61.2 (26.3)Silveria \[[@CR15]\]^a^WHQOL-BREFBED9n.r.Wilfley \[[@CR18]\]^a^IWQOL-LITEBED, sibutramine152IWQOL-LITE total score: 67.7 (18.2)BED, placebo152IWQOL-LITE total score: 68.7 (18.5)*AMI* adapted motivational interviewing, *AN* anorexia nervosa, *BED* binge eating disorder, *BN* bulimia nervosa, *ESWLS* Extended Satisfaction With Life Scale, *EQ-5D-3L* EuroQol Five Dimensional Questionnaire, *HRQoL* health-related quality of life, *IWQOL-LITE* Impact of Weight on Quality of Life--Lite, *MCS* mental component summary, *n.r*. not reported, *ORWELL* obesity related well-being, *PCS* physical component summary, *QoLP* psychological health, *QoLS* social relationships, *SD* standard deviation, *SF-12* Short-Form Disability Scale, *SF-36* Short Form 36, *WHOQOL-BREF* World Health Organization Brief Quality of Life Assessment Scale^a^Longitudinal study^b^Cross-sectional study^c^Retrospective data analysis^d^HRQoL data were presented only in figure form, HRQoL data were extracted from the figure

HRQoL of patients with BED was significantly lower than in control subjects (Table [1](#Tab1){ref-type="table"}) \[[@CR14], [@CR34], [@CR45]--[@CR47], [@CR49], [@CR51], [@CR52]\]. BED was associated with marked impairment compared to general population norms in both the physical component summary (PCS) and the mental component summary (MCS) scores of SF-36 (Masheb et al. \[[@CR48]\] PCS~BED~: 47.3, MCS~BED~: 39.7; Padierna et al. \[[@CR50]\]. PCS~BED~: 36.5, MCS~BED~: 32.0 vs. PCS~population\ norm~ = 50.0, MCS~population\ norm~ = 50.0). In the study conducted by Grenon et al. \[[@CR43]\] the EQ-5D-3L mean score of overweight/obese women with BED (0.77) was significantly lower than for a US community sample of women with a similar mean age (0.89).

Where studies evaluated HRQoL for the different eating disorders, there were no significant differences among AN, BN and BED (Table [1](#Tab1){ref-type="table"}) \[[@CR47], [@CR49], [@CR50]\]; but, decreased physical HRQoL appeared to be most evident in patients with BED. In the study by Mond et al. \[[@CR49]\] physical health measured by SF-12 was poorer in BED (PCS: 40.2) than in AN (PCS~restricting\ type~: 45.4, PCS~purging\ type~: 46.8) and BN (PCS: 49.3); however, most BED patients were obese (BMI ≥ 30) and had a higher mean age in that patient group \[mean age (standard deviation); AN restricting type: 19.31 (4.22); AN purging type: 25.53 (9.77); BN: 23.48 (6.25); BED: 34.33 (7.37)\]. These findings were consistent with those of Padierna et al. \[[@CR50]\], who reported more impaired physical health (SF-36) in BED patients (PCS: 36.5); nevertheless the differences compared to AN (PCS~restricting\ type~: 44.0, PCS~purging\ type~: 43.5) and BN (PCS: 43.0) were not statistical significant (Padierna et al. \[[@CR50]\] presented their results only in figure form, SF-36 scores were extracted from the figure).

Among subgroups of BED, obese BED patients had significantly worse HRQoL than non-obese BED patients (Table [1](#Tab1){ref-type="table"}) \[[@CR14], [@CR34], [@CR49]\]. In addition, BED was associated with more impairment in HRQoL than obesity without BED (IWQOL-LITE BED: 74.0 vs. No BED: 61.2; higher scores indicating greater impairment) \[[@CR51]\]. Obesity status more strongly affected the physical dimension of HRQoL, whereas BED status affected mental health and social functioning HRQoL \[[@CR14]\]. Among BED patients, obese BED subjects (PCS: 45.3) had significantly lower scores in PCS scores on the SF-36 compared to non-obese (PCS: 53.6) \[[@CR48]\]. Depressive symptoms were also reported to be significantly associated with lower HRQoL in patients with BED (measured with EQ-5D-3L, after controlling for age and BMI) \[[@CR43]\].

Economic burden {#Sec7}
---------------

Healthcare utilization in BED was assessed only in 8 studies \[[@CR2]--[@CR4], [@CR13], [@CR43], [@CR53]--[@CR55]\]. Healthcare costs were reported only in two studies \[[@CR43], [@CR53]\]. Reported healthcare utilization and healthcare costs data are presented in Table [2](#Tab2){ref-type="table"} and Table [3](#Tab3){ref-type="table"}.Table 2Selected healthcare utilization data for patients diagnosed with binge eating disorderFirst author, referenceSample sizeReported healthcare utilization dataDickerson \[[@CR53]\]BED sample (*n*): 50*% with any use*Weight- and eating disorder-related services24Non-weight- and eating disorder-related mental health services24Other provider-based services100Mental health medication services62Total medication services90Total health services100Grenon \[[@CR43]\]BED sample (*n*): 105*% of participants endorsing each health care domain*Family physician visits82Medication use72Diagnostic tests53Health professionals' visits51Specialist visits49Herbal remedies34Other resources16Out-patient visits15Emergency department visits13In-patient visits2Kessler \[[@CR2]\]Total sample (*n*): 24,124\
BED, lifetime prevalence: 1.9 %Lifetime treatment for emotional problems (%)5812-month treatment for emotional problems (%)37Lifetime treatment for eating disorders (%)3812-month treatment for eating disorders (%)10Marques \[[@CR13]\]Total sample (*n*): n.r. BED, lifetime prevalence:*Lifetime any service use* (%)Latino: 2.1 %Non-Latino White79Non-Latino White: 1.4 %Latino54African American: 1.5 %Asian55Asian: 1.2 %African American71Mond \[[@CR54]\]BED sample (*n*): 20*Lifetime service use* (%)Any treatmentEating58General mental health84Weight87Treatment by a mental health professionalEating23General mental health39Weight45Preti \[[@CR3]\]Total sample (*n*): 21,425\
BED, lifetime prevalence: 1.1 %*Lifetime access to service use for any emotional problem* (%)General medical24Psychiatrist16Other mental health18Non-medical professional6Complementary-alternative medical12Any lifetime treatment39*12*-*month access to service use for any emotional problem* (%)General medical17Psychiatrist10Other mental health3Non-medical professional10Complementary-alternative medical1Any 12-month treatment23First author, referenceSample sizeReported healthcare utilization dataStriegel-Moore \[[@CR55]\]BED sample (*n*): 162**12-month data**Binge eating disorderHealthy comparisonPsychiatric comparisonWhiteBlackWhiteBlackWhiteBlackObeseNon-obeseObeseNon-obeseObeseNon-obeseObeseNon-obeseObeseNon-obeseObeseNon-obeseOut-patient psychotherapist visits  %33242427030754562523Emergency department visits  %402416331713141423213862In-patient days  %111171311814431102523Out-patient physician visits mean (SD)7.9\
(10.5)4.1\
(5.8)4.4\
(8.2)7.1\
(10.1)6.2\
(8.6)3.1\
(3.6)4.1\
(7.7)3.7\
(5.3)8.2\
(10.8)6.0\
(8.1)3.3\
(3.0)4.4\
(4.4)Total service days mean (SD)21.4\
(28.1)11.8\
(21.8)17.6\
(30.1)14.9\
(23.0)8.4\
(12.7)3.4\
(3.9)4.6\
(8.4)4.8\
(7.9)16.1\
(14.0)18.4\
(23.7)6.9\
(4.6)8.5\
(10.8)Swanson \[[@CR4]\]Total sample (*n*): 10,123\
BED lifetime prevalence: 1.6 %**Lifetime service use**Binge eating disorder (%)No-eating disorder (%)Mental health specialty6029General medicine2212Human service1810Complementary and alternative medicine48 Juvenile justice15School service2021Any treatment7344Treatment specifically for eating or weight problems11n.a.*n.r.* not reported, *n.a*. not applicable, *SD* standard deviationTable 3Selected direct healthcare cost data for patients diagnosed with binge eating disorderReferenceCountry, year of pricingCost categories and reported costsAnnual costs per patient in 2012 \$Dickerson \[[@CR53]\]US 2006**Binge eating disorder**Total costs mean (SD)\$3,319 (4,050)\$3,731 Weight- and eating disorder-related services mean (SD)\$72 (176) Non-weight- and eating disorder-related mental health services mean (SD)\$415 (1,014) Other provider-based services mean (SD)\$1,925 (2,761) Mental health medication services mean (SD)\$411 (695) Total medication services mean (SD)\$906 (1,475)**Recurrent binge eating** ^a^Total costs mean (SD)\$3,588 (4,665)\$4,033 Weight- and eating disorder-related services mean (SD)\$94 (299) Non-weight- and eating disorder-related mental health services mean (SD)\$341 (840) Other provider-based services mean (SD)\$2,221 (3,818) Mental health medication services mean (SD)\$301 (637) Total medication services mean (SD)\$933 (2,087)Grenon \[[@CR43]\]Canada 2009Total cost^b^ (6-month) mean (SD)Can\$1,379 (1,252)\$2,372*Can\$* Canadian dollar, *\$* United States dollar, *SD* standard deviation, *US* United States^a^Individuals with at least 1 day per week with an objective bulimic episode over a 3-month period, with no periods of binge free time greater than 2 weeks, and did not meet DSM-IV criteria for bulimia nervosa or binge eating disorder^b^Family physician visits, medication use, diagnostic tests, health professionals' visits, specialist visits, herbal remedies, other resources, out-patient visits, emergency department visits, and in-patient visits

Striegel-Moore et al. \[[@CR55]\] analyzed the healthcare utilization in women with BED using emergency room visits, outpatient physician visits for medical care, outpatient psychotherapy visits and days spent in the hospital over the last 12 months. Compared to healthy individuals (mean total service days: 3.4--8.4), BED was associated with increased total health service use (mean total service days: 11.8--21.4), but resource utilization in BED was similar to other major psychiatric conditions (mean total service days: 6.9--18.4) (Table [2](#Tab2){ref-type="table"}). There was no significant difference in resource utilization between BED group and non-eating Axis I psychiatric disorders group.

In the included studies, only a minority of BED patients received treatment specifically for their eating disorder. Swanson et al. \[[@CR4]\] found that the lifetime service use for treatment for eating or weight problems among BED patients was only 11.9 %. In the study conducted by Kessler et al. \[[@CR2]\] 38.3 % of patients with a lifetime diagnosis of BED had received treatment specifically for an eating disorder. Mond et al. \[[@CR54]\] reported that in their study sample, 58.1 % of BED patients had received treatment for an eating problem, but 83.9 % received treatment for general mental health and 87.1 % for weight loss. Only 12.9 % of BED patients were treated by a mental health professional specifically for their eating disorder.

Marques et al. \[[@CR13]\] examined mental health service utilization for differences among ethnic groups. They found mental health service use was higher for non-Latino Whites (78.9 %) than for Latinos (54.1 %), Asians (54.5 %) or African Americans (71.1 %).

The reported annual direct healthcare costs per BED patient ranged from a low of \$2,372 \[[@CR43]\] to a high of \$3,731 \[[@CR53]\] (Table [3](#Tab3){ref-type="table"}). In one Canadian study \[[@CR43]\], the annual healthcare cost of overweight/obese women with BED was 36.5 % higher than the estimated health expenditure per capita for women in the same age group. Another US study \[[@CR53]\] compared healthcare utilization between women with BED (DSM-IV) and recurrent binge eating (individuals with at least 1 day per week with an objective bulimic episode over a 3-month period, with no periods of binge free time greater than 2 weeks, and did not meet DSM-IV criteria for BN or BED), and evaluated the effect of the number of binge eating days on healthcare costs. BED and recurrent binge eating groups did not differ significantly in total annual healthcare costs adjusted for age, BMI and self-reported depression.

Discussion {#Sec8}
==========

This systematic review of the epidemiology, and the HRQoL and economic burden of BED consolidated existing data and provides a holistic overview of impact of BED on public health. It also exposes the gaps in available data where future studies might enable a better understanding of the societal costs and overall burden of BED.

We analyzed 49 studies assessing the epidemiology, economic and HRQoL burden of BED. The methodological quality of the included studies was heterogeneous. Issues related to statistical analysis such as sensitivity analysis and addressing missing data were frequently neglected.

Based on mixed-gender surveys, the lifetime prevalence of BED appears to be about 1--2 %, with the 12-month prevalence rate of 0.1--1 % in the general population (DSM-IV) \[[@CR2]--[@CR4]\]. Point prevalence for BED was assessed in many studies; however, the results of these prevalence studies are difficult to compare because studies targeted different study populations, and used different instruments for screening for BED. Hudson et al. \[[@CR1]\] reported that using the proposed DSM-5 criteria instead DSM-IV criteria might increase the lifetime prevalence of BED with 2.9 % in women and 3.0 % in men. In consistent with these findings, Trace et al. \[[@CR42]\] also assessed higher lifetime prevalence using the proposed DSM-5 criteria (DSM-IV: 0.17 % vs. proposed DSM-5: 0.20 %). BED appears to be 1.5--6 times more prevalent among females than males \[[@CR3], [@CR4], [@CR21]\].BED can affect people of any age; but people in their 20s have higher risk than cohorts of other age groups \[[@CR3]\].

BED is found to co-occur with several mental (anxiety, depression, obsessive--compulsive disorder) and somatic disorders (diabetes, hypertension) \[[@CR2], [@CR36], [@CR40]\]. Pregnancy and the post-partum period may be periods of particularly high-risk for BED \[[@CR12], [@CR27], [@CR28], [@CR32]\]. Findings suggest that pregnancy may not only facilitate the recurrence of BED, but even contribute to its onset \[[@CR28]\].

There have been no published studies investigating the effects of BED on mortality, although it is comorbid with disorders that are known to increase mortality risks. More systematic assessment of the potential contribution of BED status to mortality risks would be of value. Some research did focus on suicidal ideations and attempts of patients with BED \[[@CR4], [@CR22], [@CR44]\]. This may suggest BED may be associated with elevated levels of suicidal ideations and even attempts compared to non-BED controls \[[@CR22]\]. Suicidal ideations in patients with BED appears to be 27.5 % (in adults) to 34.4 % (in adolescents) with the frequency of suicidal attempts 12.5 % (in adults) to 15.1 % (in adolescents) \[[@CR4], [@CR44]\].

Comorbid BED is a common problem in the obese population \[[@CR2]\]. Obesity, especially morbid obesity (BMI \> 40) accounts for significant impairment in HRQoL in BED \[[@CR14], [@CR34], [@CR48]\]. Obesity is associated with diabetes, hypertension, hypercholesterolemia, heart failure, ischemic heart disease and may have severe health consequences over time. Studies to increase understanding the long-term burden of BED in these patients are needed. Currently we lack data on the long-term health impact of BED. Obesity is also related to the increased risk for mortality, and though it may be difficult to quantify the net effect of BED on obesity and on the consequential mortality, these are important research questions.

BED significantly affects HRQoL. In BED, both physical and mental dimensions of HRQoL were significantly below population norms, with the mental component affected more \[[@CR48], [@CR50]\]. Compared to other eating disorders, BED seemed to have lower (statistically not significant) ratings in physical HRQoL \[[@CR49], [@CR50]\], which may be partially accounted for by overweight status and poor physical health \[[@CR49]\].

Although BED is a prevalent eating disorder, there is very limited literature examining the economic burden (*n* = 8) of BED \[[@CR2]--[@CR4], [@CR13], [@CR43], [@CR53]--[@CR55]\]. Additionally, available literature on its economic burden has used inconsistent measures, limiting our ability to draw reliable conclusions. BED is associated with a high rate of hospitalization, outpatient care, and emergency department use \[[@CR55]\]. BED patients rarely utilize the appropriate healthcare services specifically for their eating disorder; patients mostly receive treatment for general mental health and/or weight loss \[[@CR2], [@CR4], [@CR54]\]. This makes it difficult to sufficiently gauge the relative impact of BED on these costs. This may be partly explained in that healthcare providers have not recognized BED as disorder requiring a specific treatment. Improved diagnosis, awareness and treatment may eventually provide better data for estimating economic burden. The annual direct healthcare cost in BED appears to be higher than an age and sex matched national average \[[@CR43]\]. Dickerson et al. \[[@CR53]\] found no significant difference between the annual healthcare costs of patients with BED (DSM-IV) and recurrent binge eating.

The findings of this study should be considered in light of the following limitations. Our systematic review identified only studies published in English, in peer-reviewed journals that were indexed in the selected databases. In order to get the most up to date data, the epidemiological data were extracted only from studies published between 2009 and 2013 only. STROBE checklist was developed for the quality assessment of observational studies in which data were collected for the research purpose. Specific issues related to research using routinely collected data are not addressed in STROBE; nevertheless, we also used it for assessing the quality of those studies in which retrospective database analyses were performed. Included studies originated from 23 countries \[with over half (*n* = 25) conducted in the US\]; however, because of the low number of included articles, cultural differences could not be addressed in this review. In this review we estimated the occurrence of BED and did not study its determinants, therefore confounding was not an issue. Nevertheless, misclassification and selection bias might have occurred to some extent, since not all the studies included used the same diagnostic criteria, and the method of case ascertainment was different.

In summary, BED has a lifetime prevalence rate of 1--2 % in the general population. BED significantly affects HRQoL. It is associated with increased healthcare utilization and healthcare costs compared to individuals without an eating disorder. Obesity and especially morbid obesity account for significant impairment in BED; however, the negative health consequences of obesity can be more significant on the long run. Only a minority of patients receives a specific treatment for BED. With education of providers on the diagnosis, reporting/coding, treatment, and management of BED, data should become available to permit more accurate assessment of the HRQoL and economic burden of this disorder. Future research (i.e., longitudinal studies and randomized controlled trials) is needed to better understand long-term consequences of BED and also help with better management of this disorder.
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